|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:approvedBy
|
2001 (US)
|
|
gptkbp:ATCCode
|
gptkb:J05AB14
|
|
gptkbp:bioavailability
|
60%
|
|
gptkbp:brand
|
gptkb:Valcyte
|
|
gptkbp:CASNumber
|
gptkb:175865-59-5
|
|
gptkbp:chemicalFormula
|
C14H22N6O5
|
|
gptkbp:contraindication
|
thrombocytopenia
severe neutropenia
hypersensitivity to ganciclovir
|
|
gptkbp:developer
|
gptkb:Roche
|
|
gptkbp:drugClass
|
antiviral drug
|
|
gptkbp:eliminationHalfLife
|
4 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
valganciclovir
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits viral DNA synthesis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
390.36 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prodrugOf
|
gptkb:ganciclovir
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
diarrhea
neutropenia
thrombocytopenia
|
|
gptkbp:usedFor
|
prevention of CMV disease in transplant recipients
treatment of cytomegalovirus (CMV) infections
|
|
gptkbp:bfsParent
|
gptkb:Cytomegalovirus
gptkb:ganciclovir
gptkb:cytomegalovirus_infection
gptkb:cytomegalovirus
|
|
gptkbp:bfsLayer
|
6
|